|
The Center for Clinical and Translational Science and Training (CCTST) has announced the recipients of “T1” pilot project grants from its first funding round, which began September 1. They are Philip Howles, PhD, assistant professor, pathology and laboratory medicine; Ian Papautsky, PhD, associate professor, electrical and computer engineering; Kimberly Risma, MD, PhD, assistant professor, pediatrics, Cincinnati Children’s Hospital Medical Center (CCHMC) allergy and immunology; and Shannon Saldaña, PharmD, assistant professor, pediatrics, CCHMC clinical pharmacology and pharmacy. “T1” (translation 1) research is designed to bring laboratory findings into the clinic. Made possible by the NIH Clinical & Translational Science Award (CTSA) and institutional funds, the pilot grant program is modeled after the former CCHMC Translational Research Initiative (TRI), and available to investigators across UC and the Academic Health Center. Dr. Howles’ study, “CEL Inhibitors for Treatment of Cardiovascular Disease,” will assess whether a carboxyl ester lipase inhibitor given together with a statin will provide added benefit in the treatment of hypercholesterolemia over treatment with a statin alone. Dr. Papautsky’s multidisciplinary study,“Zinc Chip for Point of Care (POC) Monitoring in Critically Ill Children,” will work on developing a device that will allow rapid and accurate measurement of zinc levels at the bedside, which may lead to simple zinc supplementation-based therapies for critically ill patients. Co-investigators are Hector Wong, MD, professor of pediatrics and director of the CCHMC pediatric intensive care unit; Fred Beyette Jr, PhD, associate professor, electrical and computer engineering; and William Heineman, PhD, distinguished research professor, chemistry. Dr. Risma’s study, “Pathogenesis of Perforin Mutations Causing Immunodeficiency,” will help determine why some perforin mutations lead to hemophagocytic lymphohistiocytosis while others lead to milder clinical disorders or no symptoms at all. Co-investigator is Andrew Herr, PhD, associate professor, molecular genetics, biochemistry and microbiology. Dr. Saldaña’s study, “Pediatric Expert Dosing Strategies (PEDS) for Warfarin,” will study genetic differences in children taking warfarin and develop a formula to help clinicians choose a dose for effective treatment with lower risk of adverse events. Letters of intent for the next T1 funding round must be received by Friday, October 9 at 5:00 PM. Click here for more details or contact Angela Sterwerf at (513) 803-2778 or
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
.
|
